#AACR26: Xuanzhu shares dip despite phase III ALK inhibitor data

BioWorld· @BioWorld · X·2026-04-21 04:45· 2026-04-21Score60

Reading

Lung cancer: perioperative IO and KRAS NSCLC

Body

#AACR26: Xuanzhu shares dip despite phase III ALK inhibitor data
https://
bioworld.com/articles/730470 #biopharma #oncology #lungcancer #HKEX #clinical

Heat 0 · 0 likes · 0 replies · 0 reposts

Conference abstracts

4618matched by 代号 TRI-611

TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

Read the abstract →

5787matched by 代号 TRI-611

TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins and leads to regression of ALK TKI-refractory tumors

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Lauren Highfield, Nobuyuki Kondo, Aaron N. Hata, Kenneth Ngo, Jisu Lee, Prafulla C. Gokhale, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

Read the abstract →

LB013matched by 药名 lorlatinib

Lorlatinib in advanced ALK-positive non-small cell lung cancer: Efficacy, safety and exploration of predictive biomarkers for therapeutic response

Fang Wei, Linyan Tian, Huiyang Shi, Wenxin Jiang, Danru Zheng, Haiyan Xu, Yan Wang

Read the abstract →

Source: BioWorld · x.com